Rare Hematology Portfolio Real-World Evidence Update

Summary Sobi presented new clinical and real-world evidence across four rare hematology franchises at EHA 2026: PNH (pegcetacoplan), ITP (avatrombopag), HLH (emapalumab), and myelofibrosis (pacritinib). While no pivotal efficacy readouts were disclosed, the package reinforces the commercial durability and clinical positioning of multiple approved products…